Jatenzo Cost in Delaware 2026: Cash Price, Insurance, Medicaid, and Savings Options

What Is Jatenzo and Why Does It Cost More Than Other Testosterone Formulations?

Jatenzo is the first FDA-approved oral testosterone replacement therapy for adult males with primary or hypogonadotropic hypogonadism. Unlike older methyltestosterone tablets, it uses an undecanoate ester formulated in a lipid matrix that allows lymphatic absorption, bypassing first-pass hepatic metabolism. That novel delivery mechanism is the main reason its list price sits far above generic testosterone cypionate injections or generic testosterone gel.

Tolmar Pharmaceuticals holds the brand exclusively. The FDA approved Jatenzo in March 2019 based largely on the key Phase III trial by Swerdloff et al., which enrolled 166 hypogonadal men and demonstrated that 87% of subjects achieved average testosterone concentrations (C-avg) within the normal range (300 to 1 to 000 ng/dL) at steady state [1]. The drug is dosed as two 237 mg capsules twice daily with a meal containing at least 20 grams of fat, and dose titration targets a C-avg between 400 and 700 ng/dL [2].

Because Jatenzo is a Schedule III controlled substance under the Controlled Substances Act, it requires a DEA-licensed prescriber and a valid prescription at every dispense [3]. That regulatory layer adds dispensing complexity compared with many non-controlled specialty drugs, which is one reason discount cards like GoodRx produce only modest savings on controlled substances at some Delaware pharmacies.

The FDA label specifies a black-box warning about blood pressure elevation. In the Swerdloff trial, mean systolic blood pressure increased by approximately 3 to 5 mmHg, and 5% of subjects required new antihypertensive treatment [1]. Prescribers must monitor blood pressure at every visit, per FDA guidance [2].

Jatenzo Cash Price in Delaware in 2026

The retail cash price for Jatenzo at Delaware pharmacies is approximately $900 per month in 2026. This figure applies to a standard 60-capsule supply (30-day supply at two capsules twice daily). Prices at individual pharmacies can differ by $20 to $50, so calling ahead to CVS, Rite Aid, or an independent Delaware pharmacy is worthwhile.

GoodRx and similar discount programs generally do not cut the Jatenzo cash price below $820 to $880 at most Delaware locations, because Schedule III controlled substances carry a mandatory dispensing fee and because pharmacy contracts for controlled substances limit rebate pass-through [4]. Mark Cuban's Cost Plus Drugs does not currently list Jatenzo, as the drug has no generic equivalent and Tolmar has not participated in that platform.

For context, generic testosterone cypionate 200 mg/mL (10 mL vial) costs roughly $30 to $60 cash at Delaware pharmacies, making the injectable roughly 15 times cheaper per month for patients who can self-inject or visit a clinic [5]. The trade-off is needle avoidance, which for many patients justifies the higher price of an oral option.

Delaware Medicaid Coverage for Jatenzo

Delaware Medicaid (Delaware Healthy Children Program and Diamond State Health Plan) covers Jatenzo for male hypogonadism, but a prior authorization (PA) is required. Without an approved PA, the pharmacy will reject the claim at point of sale.

To obtain PA approval, the prescriber typically must document:

• A confirmed diagnosis of primary hypogonadism (hypergonadotropic) or hypogonadotropic hypogonadism based on two morning serum total testosterone measurements below 300 ng/dL, drawn on separate days.
• Clinical symptoms consistent with testosterone deficiency (fatigue, reduced libido, erectile dysfunction, or loss of muscle mass).
• A clinical rationale for oral delivery rather than a lower-cost injectable or topical formulation.

Delaware Medicaid follows the broader Medicaid preferred drug list (PDL) framework, which typically places testosterone injectables and gels in a lower tier than branded oral formulations [6]. That means the PA requirement for Jatenzo is meaningful: a prescriber who cannot justify oral-route necessity over injectable testosterone may face denial on first submission.

If denied, Delaware Medicaid enrollees have the right to a formal appeal. The appeal window is typically 30 days from the denial notice. HealthRX clinicians can prepare a detailed letter of medical necessity citing the FDA label, the Swerdloff trial data, and any patient-specific contraindication to injections or topical testosterone (e.g., skin conditions, needle phobia with documented clinical impact, or caregiver exposure risk from topical gel) [1][2].

Commercial Insurance Coverage for Jatenzo in Delaware

Coverage of Jatenzo by commercial insurers in Delaware varies considerably by plan and formulary year. Some key data points for 2026:

• Tier placement. Most commercial plans that do cover Jatenzo place it on Tier 3 (preferred brand) or Tier 4 (non-preferred brand). A Tier 4 placement typically means a copay of $80 to $150 per 30-day fill after the deductible is met.
• Step therapy. Several Delaware plans require documented failure of at least one prior testosterone formulation (usually an injectable or gel) before approving Jatenzo. This step-therapy requirement is common on ACA marketplace plans and some employer-sponsored PPOs.
• Excluded plans. Short-term health plans and certain health-sharing ministries sold in Delaware do not cover Jatenzo. Patients on those plans should assume full cash-pay cost.

The American Association of Clinical Endocrinology (AACE) 2022 guidelines state that "testosterone replacement therapy should be individualized based on the patient's clinical needs, preferences, and comorbidities, including route of administration" [7]. That language supports medical necessity arguments for oral testosterone when a patient has documented reasons to avoid injections or transdermal products.

To confirm your plan's coverage before filling, call the member services number on your insurance card and ask specifically: "Is NDC 70654-321-30 (Jatenzo 237 mg, 60 capsules) covered under my pharmacy benefit, and what tier is it on for 2026?" Getting a reference number for that call protects you if the claim is later rejected.

The Tolmar Savings Card: How It Works for Delaware Patients

Tolmar offers a manufacturer copay savings card for Jatenzo. For commercially insured patients who qualify, the card can reduce the out-of-pocket copay to as low as $0 per month, subject to a monthly maximum benefit and an annual cap.

Key program details as of 2026:

• Eligibility is limited to patients with commercial (private) insurance. Medicaid, Medicare Part D, and other federal or state government-funded insurance are explicitly excluded.
• The savings card cannot be used as primary payment; the patient must have an active commercial insurance plan that processes the claim first.
• Delaware patients can enroll online at the Tolmar Jatenzo savings card portal or ask the prescribing clinic to provide the enrollment card at the time of prescription.
• The maximum annual savings limit typically caps the benefit at around $3,600 per year (equivalent to six months of full cash-pay price), though Tolmar adjusts terms annually.

Because the savings card is not usable with Medicaid, Delaware Medicaid patients should not expect this program to apply to their fills. For those patients, the PA pathway described above is the correct route to covered access [6].

Legal Compounded Oral Testosterone Undecanoate in Delaware

Compounded oral testosterone undecanoate is legally available in Delaware through licensed 503A compounding pharmacies. Under Section 503A of the Federal Food, Drug, and Cosmetic Act, a licensed pharmacist may compound a drug product, including testosterone undecanoate in an oral capsule, when a prescriber issues a valid patient-specific prescription and the drug is not commercially available in the exact strength or formulation needed by that patient [8].

Delaware Board of Pharmacy rules require that 503A pharmacies serving Delaware patients hold a current Delaware pharmacy license and comply with USP 795 standards for non-sterile compounding [9]. Pharmacies operating only under a 503B outsourcing facility designation (which permits large-batch manufacturing for office use) face different federal restrictions and generally cannot dispense directly to retail patients without a patient-specific prescription.

Compounded oral testosterone undecanoate typically costs between $30 and $120 per month, depending on the pharmacy and the prescribed strength, compared with the $900 brand price. That difference is substantial. However, there are trade-offs:

• Compounded products are not FDA-approved and have not undergone the same bioavailability testing as the brand Jatenzo [2].
• Batch-to-batch potency can vary. A 2019 analysis published in Drug and Therapeutics Bulletin found potency variability of 10 to 15% in some compounded hormone preparations, though that analysis focused primarily on topical products [10].
• Insurance does not typically reimburse 503A compounded products, so cost savings are realized only on the cash-pay side.

For patients with commercial insurance and an active Tolmar savings card, the compounded route may offer no real financial advantage and introduces the bioavailability uncertainty. For uninsured or underinsured Delaware patients who cannot obtain PA through Medicaid, compounded oral testosterone undecanoate from a licensed 503A pharmacy may be the most affordable legal option.

Telehealth Prescribing of Jatenzo in Delaware

Delaware permits telehealth prescribing of Jatenzo for established patients with a documented diagnosis of hypogonadism. The prescriber must hold a valid Delaware medical license and must satisfy the DEA's requirements for controlled substance prescribing, which since the end of the federal COVID-19 public health emergency have required an in-person evaluation prior to initiating a Schedule III controlled substance via telemedicine for most providers [11].

There is an important nuance: DEA proposed rules for telemedicine prescribing of controlled substances issued in 2023 would allow registered telemedicine platforms to prescribe Schedule III-V substances with an audio-visual encounter and specific documentation, but those rules remained in a finalization process as of early 2026 [11]. Delaware patients seeking Jatenzo through a telehealth platform should confirm that the platform's prescribers comply with the current DEA framework in place at the time of their appointment.

HealthRX clinicians conduct a detailed intake that includes laboratory review (two morning total testosterone levels, LH, FSH, CBC, PSA, and metabolic panel), symptom assessment, and blood pressure measurement before initiating Jatenzo. After the initial in-person or appropriately compliant telehealth evaluation, follow-up titration visits can often proceed via telehealth, with testosterone C-avg measured 3 to 5 hours post-dose at weeks 4 and 12 [1][2].

How Jatenzo Compares to Other Testosterone Options on Cost and Access in Delaware

Delaware patients considering testosterone replacement therapy have several options beyond Jatenzo. The table below summarizes the approximate 2026 cash prices for common formulations at Delaware pharmacies.

| Formulation | Generic Available | Approx. Cash Price/Month (DE, 2026) | |---|---|---| | Jatenzo 237 mg oral capsule | No | ~$900 | | Testosterone cypionate inj. (200 mg/mL, 10 mL) | Yes | ~$30 to $60 | | Testosterone enanthate inj. (200 mg/mL, 10 mL) | Yes | ~$40 to $70 | | Testosterone gel 1% (generic AndroGel) | Yes | ~$80 to $150 | | Testosterone gel 1.62% (generic) | Yes | ~$100 to $180 | | Compounded oral TU (503A) | N/A | ~$30 to $120 | | Clomiphene citrate (off-label secondary hypogonadism) | Yes | ~$20 to $60 |

The Endocrine Society's 2018 Clinical Practice Guideline on testosterone therapy states: "We suggest testosterone therapy for men with classic androgen deficiency syndromes who have a low serum testosterone concentration and symptoms/signs of androgen deficiency." The guideline explicitly notes that route selection should account for "patient preference, cost, and availability" [12].

For patients whose primary goal is needle avoidance and who have commercial insurance with the Tolmar savings card, Jatenzo's effective cost can drop to near zero per month, making it competitive with generics on a net cost basis. For uninsured patients paying cash, injectable testosterone cypionate or a compounded oral product represents the more accessible path to treatment.

The HealthRX clinical team uses a three-question decision framework when evaluating Delaware patients for Jatenzo versus alternative testosterone formulations:

1. Does the patient have confirmed hypogonadism by two low morning testosterone values and consistent symptoms, per Endocrine Society criteria? [12]
2. Does the patient have a clinical or documented personal reason to avoid injections and topical products (e.g., contact transfer risk to children or partners, skin condition, needle phobia with functional impairment)?
3. What is the patient's payer status, and can the Tolmar savings card or a Delaware Medicaid PA be secured before the first fill?

Only when all three questions are addressed does the team proceed to a Jatenzo prescription, because the blood pressure monitoring obligation (office check at baseline, 4 weeks, and 12 weeks) and the Schedule III dispensing process add clinical and logistical weight to every Jatenzo initiation [1][2].

Monitoring Requirements That Affect the Total Cost of Jatenzo Therapy in Delaware

The out-of-pocket cost of Jatenzo is not limited to the pharmacy line item. The FDA label requires blood pressure monitoring at every clinical encounter, and the prescribing information recommends checking serum testosterone C-avg (drawn 3 to 5 hours after the morning dose) at weeks 4 and 12 of therapy, and periodically thereafter [2].

For Delaware patients on commercial insurance, lab costs for testosterone panels (CPT 84402 or 84403) are typically covered after deductible under preventive or diagnostic benefit categories, but cost-sharing varies. Uninsured patients paying cash for labs at a commercial draw site (LabCorp or Quest in Delaware) can expect $40 to $80 per testosterone total test without a discount program. Using a direct-pay lab service can reduce that to $25 to $50 per draw [5].

PSA monitoring (CPT 86316) is also recommended at baseline and periodically in men over 40, per FDA labeling [2]. A PSA test costs roughly $20 to $60 cash at Delaware draw sites.

Adding two to four lab visits per year at an average of $60 to $120 per visit brings the realistic annual monitoring cost for an uninsured Delaware patient on Jatenzo to $240 to $480 on top of the pharmacy cost.

Practical Steps to Get Jatenzo at the Lowest Cost in Delaware

Getting the lowest possible price on Jatenzo in Delaware involves a defined sequence of actions.

Step 1. Confirm the diagnosis. Two morning serum total testosterone measurements below 300 ng/dL on separate days, along with symptoms, are required for Jatenzo prescribing per FDA label indications [2]. A single low value is insufficient for prescribing or insurance approval.

Step 2. Identify your payer. If you have Delaware Medicaid, pursue the PA pathway immediately. If you have commercial insurance, verify tier placement and step-therapy requirements before your appointment. If you are uninsured, compare the Tolmar patient assistance program (for very low-income patients) against the 503A compounded route.

Step 3. Enroll in the Tolmar savings card at the time of prescribing if you have commercial insurance. The card is activated before the first fill, not after.

Step 4. Use a Delaware pharmacy that processes manufacturer copay cards, as some independent pharmacies or mail-order services do not participate in Tolmar's third-party adjudication network.

Step 5. Schedule the week-4 testosterone C-avg draw proactively, because dose titration may require moving to 316 mg twice daily or down to 158 mg twice daily [2]. Early titration to the correct dose avoids wasted fills at the wrong strength.

Step 6. Monitor blood pressure at home with a validated cuff between office visits and report any sustained increase above 130/80 mmHg to your prescriber promptly, per the FDA black-box warning [2][3].

A 12-month retrospective analysis of testosterone therapy initiation published in JAMA Internal Medicine found that 23% of men started on brand testosterone formulations switched to a lower-cost alternative within 6 months, most often due to cost-related non-adherence [13]. Starting the prior authorization or savings card process before the prescription is written reduces the chance of that first-fill surprise.